Solene Masloh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Solene Masloh has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anne Chevrel
Affilogic, 24 Rue de la Rainière, 44300 Nantes, France
1 shared publication - Fabien Gosselet
Univ. Artois, UR 2465, Blood-brain barrier laboratory (LBHE), F-62300 Lens, France
1 shared publication - Leonardo Scapozza
Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
1 shared publication - Magali Zeisser Labouebe
School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, 1201 Geneva, Switzerland
1 shared publication - Maxime Culot
UR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois, Lens, France
1 shared publication
Latest Publications
- Open Access
- 5 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1415
Challenges and Opportunities in the Oral Delivery of Recombinant Biologics
Recombinant biological molecules are at the cutting-edge of biomedical research thanks to the significant progress made in biotechnology and a better understanding of subcellular processes implicated in several diseases. Given their ability to induce a potent response, these molecules are becoming the drugs of choice for multiple pathologies. However, unlike conventional drugs which are mostly ingested, the majority of biologics are currently administered parenterally. Therefore, to improve their limited bioavailability when delivered orally, the scientific community has devoted tremendous efforts to develop accurate cell- and tissue-based models that allow for the determination of their capacity to cross the intestinal mucosa. Furthermore, several promising approaches have been imagined to enhance the intestinal permeability and stability of recombinant biological molecules. This review summarizes the main physiological barriers to the oral delivery of biologics. Several preclinical in vitro and ex vivo models currently used to assess permeability are also presented. Finally, the multiple strategies explored to address the challenges of administering biotherapeutics orally are described.
- 5 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1415
Open AccessChallenges and Opportunities in the Oral Delivery of Recombinant Biologics
Recombinant biological molecules are at the cutting-edge of biomedical research thanks to the significant progress made in biotechnology and a better understanding of subcellular processes implicated in several diseases. Given their ability to induce a potent response, these molecules are becoming the drugs of choice for multiple pathologies. However, unlike conventional drugs which are mostly ingested, the majority of biologics are currently administered parenterally. Therefore, to improve their limited bioavailability when delivered orally, the scientific community has devoted tremendous efforts to develop accurate cell- and tissue-based models that allow for the determination of their capacity to cross the intestinal mucosa. Furthermore, several promising approaches have been imagined to enhance the intestinal permeability and stability of recombinant biological molecules. This review summarizes the main physiological barriers to the oral delivery of biologics. Several preclinical in vitro and ex vivo models currently used to assess permeability are also presented. Finally, the multiple strategies explored to address the challenges of administering biotherapeutics orally are described.